|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
108,000,000 |
Market
Cap: |
N/A |
Last
Volume: |
5,721,727 |
Avg
Vol: |
2,608,358 |
52
Week Range: |
$73.89 - $73.89 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Welch Daniel G |
Chairman, CEO and President |
|
2012-06-04 |
4 |
A |
$10.10 |
$606,000 |
D/D |
60,000 |
206,601 |
|
- |
|
Verwiel Frank |
Director |
|
2012-06-04 |
4 |
A |
$10.10 |
$25,250 |
D/D |
2,500 |
6,725 |
|
- |
|
Seiwert Scott |
SVP, Rsearch & Technical Dev. |
|
2012-05-14 |
4 |
D |
$11.83 |
$2,780 |
D/D |
(235) |
39,669 |
|
- |
|
Armstrong Marianne |
SVP Ch Reg & Drug Safety Off |
|
2012-05-14 |
4 |
D |
$11.83 |
$6,447 |
D/D |
(545) |
37,762 |
|
- |
|
Hodgman John |
SVP-Finance & CFO |
|
2012-05-14 |
4 |
D |
$11.83 |
$9,203 |
D/D |
(778) |
50,906 |
|
- |
|
Porter Steven Bryant |
Chief Medical Officer |
|
2012-05-14 |
4 |
D |
$11.83 |
$6,447 |
D/D |
(545) |
37,762 |
|
- |
|
Steele Robin Joan |
SVP, GC, Secretary |
|
2012-05-14 |
4 |
D |
$11.83 |
$6,447 |
D/D |
(545) |
8,797 |
|
- |
|
Bradford Williamson Z III |
SVP-Clinical Science |
|
2012-05-14 |
4 |
D |
$11.83 |
$4,661 |
D/D |
(394) |
56,392 |
|
- |
|
Welch Daniel G |
Chairman, CEO and President |
|
2012-05-14 |
4 |
D |
$11.75 |
$24,248 |
D/D |
(2,064) |
212,601 |
|
- |
|
Seiwert Scott |
SVP, Rsearch & Technical Dev. |
|
2012-05-11 |
4 |
D |
$11.58 |
$7,586 |
D/D |
(655) |
33,904 |
|
- |
|
Armstrong Marianne |
SVP Ch Reg & Drug Safety Off |
|
2012-05-11 |
4 |
D |
$11.58 |
$7,586 |
D/D |
(655) |
38,307 |
|
- |
|
Hodgman John |
SVP-Finance & CFO |
|
2012-05-11 |
4 |
D |
$11.58 |
$7,586 |
D/D |
(655) |
51,684 |
|
- |
|
Porter Steven Bryant |
Chief Medical Officer |
|
2012-05-11 |
4 |
D |
$11.58 |
$7,586 |
D/D |
(655) |
38,307 |
|
- |
|
Steele Robin Joan |
SVP, GC, Secretary |
|
2012-05-11 |
4 |
D |
$11.58 |
$7,586 |
D/D |
(655) |
9,342 |
|
- |
|
Bradford Williamson Z III |
SVP-Clinical Science |
|
2012-05-11 |
4 |
D |
$11.58 |
$5,478 |
D/D |
(473) |
56,786 |
|
- |
|
Cohen Alan Howard |
SVP, Medical Affairs |
|
2012-05-11 |
4 |
D |
$11.58 |
$7,586 |
D/D |
(655) |
16,518 |
|
- |
|
Welch Daniel G |
Chairman, CEO and President |
|
2012-05-10 |
4 |
D |
$11.54 |
$33,862 |
D/D |
(2,935) |
214,665 |
|
- |
|
Bienaime Jean Jacques |
Director |
|
2012-04-06 |
4 |
A |
$0.00 |
$0 |
D/D |
4,225 |
4,225 |
|
- |
|
Verwiel Frank |
Director |
|
2012-04-06 |
4 |
A |
$0.00 |
$0 |
D/D |
4,225 |
4,225 |
|
- |
|
Leff Jonathan A |
EVP of R&D |
|
2012-03-07 |
4 |
A |
$0.00 |
$0 |
D/D |
75,200 |
75,200 |
|
- |
|
Simon Howard Allan |
SVP-Human Resources |
|
2011-12-09 |
4 |
D |
$16.54 |
$52,285 |
D/D |
(3,161) |
20,957 |
|
- |
|
Armstrong Marianne |
SVP Ch Reg & Drug Safety Off |
|
2011-12-09 |
4 |
D |
$16.54 |
$91,469 |
D/D |
(5,530) |
38,962 |
|
- |
|
Seiwert Scott |
SVP, Rsearch & Technical Dev. |
|
2011-12-09 |
4 |
D |
$16.54 |
$70,595 |
D/D |
(4,268) |
34,559 |
|
- |
|
Cohen Alan Howard |
SVP, Medical Affairs |
|
2011-12-09 |
4 |
D |
$16.54 |
$52,285 |
D/D |
(3,161) |
17,173 |
|
- |
|
Hodgman John |
SVP-Finance & CFO |
|
2011-12-09 |
4 |
D |
$16.54 |
$91,469 |
D/D |
(5,530) |
52,339 |
|
- |
|
772 Records found
|
|
Page 7 of 31 |
|
|